Rucaparib

Generic Name: Rucaparib

Brand Names: Rubraca

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₈FN_₃O

CAS Number: 283173-50-2

Unique Ingredient Identifier: 8237F3U7EH

Background: Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...

Indication: Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer

Associated Therapies: Maintenance therapy

Clinical Trials

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Phase 2

Completed

Conditions: Endometrial Cancer
Uterine Carcinosarcoma

Interventions: Drug: Rucaparib
Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2018-10-03

Last Posted Date: 2023-08-31

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 30

Registration Number: NCT03694262

Locations: 🇺🇸
Froedtert Lutheran Memorial Hospital, Milwaukee, Wisconsin, United States
🇺🇸
St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States
🇺🇸
Mount Sinai, New York, New York, United States

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Phase 2

Active, not recruiting

Conditions: Mesothelioma, Malignant

Interventions: Drug: pembrolizumab & bemcentinib
Drug: Atezolizumab & Bevacizumab
Drug: Dostarlimab and Niraparib
Drug: Rucaparib
Drug: Abemaciclib

First Posted Date: 2018-08-31

Last Posted Date: 2023-03-14

Lead Sponsor: University of Leicester

Target Recruit Count: 186

Registration Number: NCT03654833

Locations: 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2018-08-21

Last Posted Date: 2024-08-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT03639935

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Endometrial Cancer

Interventions: Drug: Placebo Oral Tablet
Drug: Rucaparib

First Posted Date: 2018-08-06

Last Posted Date: 2024-10-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 79

Registration Number: NCT03617679

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1

Terminated

Conditions: Endometrial Cancer
Prostate Cancer

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2018-06-28

Last Posted Date: 2021-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT03572478

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage IV Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Rucaparib

First Posted Date: 2018-06-15

Last Posted Date: 2024-10-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT03559049

Locations: 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Rucaparib
Radiation: Radiotherapy

First Posted Date: 2018-05-31

Last Posted Date: 2024-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT03542175

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Rucaparib in Nonmetastatic prOstAte With BRCAness

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Rucaparib

First Posted Date: 2018-05-23

Last Posted Date: 2024-03-13

Lead Sponsor: University of Utah

Target Recruit Count: 7

Registration Number: NCT03533946

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Partial Response
Newly Diagnosed
Complete Response
Primary Peritoneal
Epithelial Ovarian Cancer
Fallopian Tube Cancer
FIGO Stage III-IV

Interventions: Drug: Placebo Oral Tablet
Drug: Rucaparib
Drug: Nivolumab
Drug: Placebo IV Infusion

First Posted Date: 2018-05-11

Last Posted Date: 2024-07-12

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 1000

Registration Number: NCT03522246

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
UCLA Women's Health Clinical Research Unit, Los Angeles, California, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 234 locations

A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: Rucaparib

First Posted Date: 2018-04-17

Last Posted Date: 2023-06-09

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 29

Registration Number: NCT03499444

Locations: 🇯🇵
Department of Gynecologic Oncology, Saitama Medical Univeristy international Medical Center, Hidaka, Saitama, Japan
🇯🇵
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji, Tokyo, Japan
🇯🇵
Division of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy